Marketed in 55 countries across Europe, the Americas, and the Asia-Pacific region, Femara is a globally distributed brand of letrozole, classified within endocrine antitumour therapy as an inhibitor of estrogen synthesis. For an international reader — whether a patient continuing treatment abroad, a family member helping with logistics, or someone newly prescribed the medication in an unfamiliar country — the page is intended to clarify what the brand contains and where it sits internationally.
Letrozole is used in the management of breast cancer, particularly in hormone-receptor–positive settings, and is prescribed alongside or following other modalities such as surgery and chemotherapy as part of an endocrine treatment plan. The structured indication list further down this page details the registered uses recognised across the markets where Femara is sold, and is the authoritative reference for the regulatory wording in each country.
Because Femara is so broadly distributed, travellers and expatriates frequently encounter the same medication abroad — sometimes still labelled as Femara, sometimes as a letrozole-containing generic following patent expiry. Markets where the brand is registered include Canada, Brazil, Australia, Belgium, and China, but regulatory packaging, prescription pathways, and the mix of available generics differ considerably from one country to another. A local pharmacist can confirm whether a letrozole product on the shelf corresponds to the medication a patient has been taking at home.
Other medications in the endocrine-therapy and estrogen-synthesis-inhibitor categories are sold in many of the same markets under different molecules and brand names, although they are not freely interchangeable. Anyone managing oncology treatment across borders should treat substitution as a clinical decision and coordinate it with the treating oncologist before any change is made.
Femara is prescribed in the management of breast cancer as part of endocrine therapy. Letrozole works by inhibiting the synthesis of estrogens, which is the basis for its use in hormone-receptor–positive disease in adult patients, including settings adjacent to surgery and chemotherapy. The structured indication block further down this page lists the registered uses recognised by national regulators in the markets where Femara is sold.
Femara contains letrozole, classified as an inhibitor of estrogen synthesis and used in endocrine antitumour therapy. Letrozole is the same molecule whether sold under the Femara brand or as a generic — internationally, the same active ingredient circulates under multiple commercial names, particularly in markets where the original patent has expired and several manufacturers produce letrozole-containing products in parallel.
Femara is registered for sale in 55 countries, spanning Europe, Latin America, the Asia-Pacific region, and parts of North America. Examples include Brazil, China, Canada, Australia, Belgium, and Bangladesh. If your country is not represented in the list shown on this page, a local pharmacist can usually confirm whether letrozole is available in that market under a different brand name or as a generic.
Letrozole is sold under several brand names worldwide, particularly in markets where the original patent has expired and generic manufacturers have entered. Other medications within the broader endocrine-therapy and estrogen-synthesis-inhibitor categories also exist, although they are not interchangeable without medical guidance. To identify a local letrozole-containing product, search the active ingredient on Pill2Trip or ask a pharmacist in your destination country.
Yes. Femara is a prescription medication, and endocrine therapy in oncology is calibrated to a patient's diagnosis, treatment plan, and individual circumstances. This is especially relevant for patients travelling or relocating between countries, since prescription requirements, branded packaging, and available generics differ across regulatory regimes. Any decision to start, continue, switch, or substitute letrozole therapy should sit with the treating oncologist or healthcare provider.
